- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00752570
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the colon or rectum in patients who are presenting with metastatic disease
- One and only one prior chemotherapy regimen for metastatic disease consisting of the combination of a fluoropyrimidine-based chemotherapy and an oxaliplatin-based chemotherapy. Prior adjuvant chemotherapy used prior to the onset of metastatic disease is permitted
- At least one uni dimensionally measurable lesion per modified RECIST criteria. All sites of disease must be evaluated <= 28 days before randomization
- Radiographically documented disease progression per modified RECIST criteria either while receiving or <= 6 months after the last dose of prior chemotherapy regimen for metastatic disease
- ECOG performance status of 0 or 1
- Man or woman >= 18 years of age
- Adequate end organ assessments by laboratory studies (hematological and chemistries)
- Life expectancy >= 3 months
Exclusion Criteria:
Exclude subjects with a history of prior malignancy, except:
- Malignancy treated with curative intent and with no known active disease present for >= 3 years before enrollment and felt to be at low risk for recurrence by treating physician
- Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease
- Adequately treated cervical carcinoma in situ without evidence of disease
- Prostatic intraepithelial neoplasia without evidence of prostate cancer
- Prior irinotecan therapy
- Systemic chemotherapy, hormonal therapy, or immunotherapy <= 21 days prior to randomization
- Experimental or approved proteins/antibodies (eg, bevacizumab) <= 30 days prior to randomization
- Clinically significant cardiac disease within 12 months prior to randomization, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication, percutaneous transluminal coronary angioplasty/stent
- Known allergy or hypersensitivity to irinotecan, 5 FU (known dihydropyrimidine dehydrogenase deficiency) or leucovorin
- Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as >= CTC grade 2 [CTCAE version 3.0])
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: 2
AMG 386 placebo QW, FOLFIRI Q2W
|
AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386. FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours. FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest. |
Aktiv komparator: 1
Arm 1 : AMG 386 10 mg/kg QW, FOLFIRI Q2W
|
Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386. FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours. FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest.
AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
To estimate the treatment effect as measured by progression free survival (PFS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo.
Tidsram: The time frame will be event driven and will occur when 100 subjects have experienced a PFS event (radiographic disease progression or death).
|
The time frame will be event driven and will occur when 100 subjects have experienced a PFS event (radiographic disease progression or death).
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
To evaluate other measures of efficacy or clinical response including objective response rate (ORR), duration of response (DOR), overall survival (OS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo
Tidsram: Treatment phase or until disease progression
|
Treatment phase or until disease progression
|
To evaluate progression free survival and measures of efficacy by KRAS status
Tidsram: Treatment phase
|
Treatment phase
|
To evaluate patient reported outcomes (PROs), relative dose intensity, incidence of anti AMG 386 antibody formation, pharmacokinetics of AMG 386 (Cmax and AUC) and safety (incidence of AEs and significant laboratory changes)
Tidsram: Throughout study
|
Throughout study
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer efter plats
- Neoplasmer, körtel och epitel
- Neoplasmer i matsmältningssystemet
- Gastrointestinala sjukdomar
- Kolonsjukdomar
- Tarmsjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Carcinom
- Kolorektala neoplasmer
- Gastrointestinala neoplasmer
- Kolonneoplasmer
- Läkemedels fysiologiska effekter
- Antineoplastiska medel
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Trebananib
Andra studie-ID-nummer
- 20070307
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Carcinom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeOral Cavity Carcinom | Oral intraepitelial neoplasiFörenta staterna
-
Endo PharmaceuticalsAvslutad
-
Indira Gandhi Medical College, ShimlaOkänd
-
Ontario Clinical Oncology Group (OCOG)Avslutad
-
Yueyong XiaoOkänd
-
Michigan State UniversityAvslutad
-
Washington University School of MedicineAvslutad
-
Stanford UniversityAvslutad
-
BayerAmgenAvslutadCarcinomFörenta staterna
Kliniska prövningar på AMG 386 Placebo
-
AmgenAvslutadAvancerat njurcellscancer
-
AmgenAvslutadCarcinom | Cancer | Äggstockscancer | Äggledarcancer | Fasta tumörer | Onkologi | Tumörer | Metastaser | Gynekologiska maligniteterBelgien, Förenta staterna, Australien
-
National Cancer Institute (NCI)AvslutadÅterkommande mjukdelssarkom från vuxna | Steg III Mjukvävnadssarkom för vuxna | Steg IV Mjukvävnadssarkom för vuxna | Vuxen angiosarkomFörenta staterna
-
AmgenAvslutadÄggstockscancer | Äggledarcancer | Primär peritoneal cancer
-
AmgenAvslutadCancer | Bröstcancer | Bröstneoplasmer | Metastaserande cancer | Brösttumörer | Fasta tumörer | Onkologi | Tumörer | Metastaser | Lokalt återkommande och metastaserad bröstcancerFörenta staterna, Belgien, Frankrike
-
AmgenAvslutadÄggstockscancer | Äggledarcancer | Primär peritoneal cancerFörenta staterna, Frankrike, Italien, Spanien, Storbritannien, Belgien, Kanada, Polen, Schweiz, Korea, Republiken av, Ryska Federationen, Hong Kong, Portugal, Sydafrika, Israel, Rumänien, Bulgarien, Grekland, Australien, Sverige, Japa... och mer
-
AmgenAvslutadNedsatt njurfunktion | Avancerade solida tumörer | NjursjukdomFörenta staterna
-
National Cancer Institute (NCI)AvslutadNeoplasma i centrala nervsystemet | Fast neoplasmaFörenta staterna, Kanada
-
AmgenAvslutad